Kazia on Wednesday announced positive preclinical data for its paxalisib drug in triple-negative breast cancer. The company’s stock is soaring over 77% on exceptionally high and unusual trading volume.
Kazia on Wednesday announced positive preclinical data for its paxalisib drug in triple-negative breast cancer. The company’s stock is soaring over 77% on exceptionally high and unusual trading volume.
Copyright © Louis Velazquez. All Rights Reserved.